CCCC — C4 Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1662579 ·
Last close
$2.98
Market Cap
$366.61M
52W High
$5.17
52W Low
$1.69
ADV30
2,157,533
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 6,641,000 | — | -26,423,000 | -23,635,000 | 359,404,000 | 78,610,000 | 112,139,000 |
| Mar 2026 | 6,152,000 | — | -27,785,000 | -25,129,000 | 328,861,000 | 61,274,000 | 94,614,000 |
| Dec 2025 | 11,016,000 | — | -23,145,000 | -20,486,000 | 359,075,000 | 74,603,000 | 102,488,000 |
| Sep 2025 | 11,230,000 | — | -23,679,000 | -32,166,000 | 265,488,000 | 58,809,000 | 111,080,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-95,353,000
Investing CF
$-21,573,000
Financing CF
$126,907,000
CapEx
$-486,000
Dividends Paid
—
Buybacks
$-238,000
EPS Diluted TTM
$-1.19
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-763,822,000
Inventory
—
Receivables
$2,883,000
ST Investments
$174,397,000
EBIT TTM
$-103,110,000
Pretax Income TTM
$-103,680,000
Interest Exp TTM
$0
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$35,039,000
EBITDA
$-99,448,000
Free Cash Flow
$-43,664,000
Enterprise Value
$235,013,232
Total Cash
$253,663,008
Total Debt
$56,858,000
Shares Out
123,025,136
Trailing EPS
$-0.91
Book Value
$2.01
ROE
-48.1%
ROA
-19.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 35,947,000 | -104,489,000 | -104,994,000 | 359,075,000 | 102,488,000 | 256,587,000 | -98,694,000 |
| Dec 2024 | 35,584,000 | -117,177,000 | -105,316,000 | 349,602,000 | 133,616,000 | 215,986,000 | -65,157,000 |
| Dec 2023 | 20,756,000 | -139,031,000 | -132,493,000 | 376,451,000 | 130,337,000 | 246,114,000 | -106,838,000 |
| Dec 2022 | 31,096,000 | -129,534,000 | -128,175,000 | 430,840,000 | 141,606,000 | 289,234,000 | -105,939,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.00
Max Pain — expiry 2027-01-15
max pain strike: $3.00 · spot: $3.12 · call oi: 5,364 · put oi: 164
Expected Move to 2027-01-15:
±$1.20
(38.52%) —
implied range
$1.92 –
$4.32
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FENC | FENNEC PHARMACEUTICALS INC. | $371.89M | $10.60 | — |
| CABA | Cabaletta Bio, Inc. | $350.96M | $2.07 | — |
| AGEN | AGENUS INC | $384.47M | $8.54 | — |
| SRZN | Surrozen, Inc./DE | $347.20M | $29.54 | — |
| ZURA | Zura Bio Ltd | $387.15M | $4.04 | — |
News headlines (Yahoo Finance, 1h cache)
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
2026-09-23 13:40 · Yahoo
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd I
2026-09-03 11:00 · Yahoo
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
2026-08-11 12:15 · Yahoo
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
2026-07-03 16:00 · Yahoo
C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D
2026-06-11 11:46 · Yahoo
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
2026-06-01 16:00 · Yahoo
C4 Therapeutics to Participate in Upcoming Conferences
2026-05-20 11:00 · Yahoo
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-18 20:01 · Yahoo
C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets
2026-05-15 13:15 · Yahoo
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
2026-05-12 12:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.